

1. Name of the medicinal product

Verbital-100 (Phenobarbital tablet BP 100 mg).

2. Qualitative and quantitative composition Qualitative formula

Each uncoated tablet contains Phenobarbital BP Excipients q.s.

Quantitative formula

Each uncoated tablet containsPhenobarbitalBP 100 mgExcipientsq.s.

3. Pharmaceutical form

Oral Solid Dosage form (tablet)

4. Clinical particulars

4.1 Therapeutic indications

Phenobarbital is recommended for all forms of epilepsy (except absence seizures).

4.2 Posology and method of administration

Adults: 60-180mg at night

Child: 5-8mg/kg daily

Elderly: Phenobarbital clearance diminishes in the elderly. Therefore the dose of phenobarbital is usually lower in elderly patients.

The dose of phenobarbital should be adjusted to meet the needs of individual patients. This usually requires plasma concentration of 15 to 40 micrograms/ml (65 to 170 micromoles/litre). *Method of Administration*

For oral administration

r or orar administration

4.3 Contraindications

Phenobarbital should not be given to patients with:

- Known hypersensitivity to phenobarbital, other barbiturates or other ingredients in the tablet
- Acute intermittent porphyia
- Severe respiratory depression
- Severe renal or hepatic impairment.

4.4 Special warnings and precautions for use

Suicidal ideation and behaviour have been reported in patients treated with anti-epileptic agents in several indications. A meta-analysis of randomised placebo controlled trials of anti-epileptic

Page **18** of **78**

drugs has also shown a small increased risk of suicidal ideation and behaviour. The mechanism of this risk is not known and the available data do not exclude the possibility of an increased risk for phenobarbital.

Therefore patients should be monitored for signs of suicidal ideation and behaviours and appropriate treatment should be considered. Patients (and caregivers of patients) should be advised to seek medical advice should signs of suicidal ideation or behaviour emerge.

Steven-Johnson syndrome and toxic epidermal necrolysis

Life-threatening cutaneous reactions Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) have been reported with the use of phenobarbital. Patients should be advised of the signs and symptoms and monitored closely for skin reactions. The highest risk for occurrence of SJS or TEN is within the first weeks of treatment.

If symptoms or signs of SJS or TEN (e.g. progressive skin rash often with blisters or mucosal lesions) are present, Phenobarbital treatment should be discontinued. The best results in managing SJS and TEN come from early diagnosis and immediate discontinuation of any suspect drug. Early withdrawal is associated with a better prognosis.

If the patient has developed SJS or TEN with the use of phenobarbital, phenobarbital must not be re-started in this patient at any time.

Care should be used in the following situations:

• Patients with the rare hereditary problems of galactose intolerance, the lapp lactase deficiency or glucose – galactose malabsorption should not take this medicine

- Respiratory depression (avoid if severe)
- Young, debilitated or senile patients
- Renal impairment
- Existing liver disease

• Sudden withdrawal should be avoided as severe withdrawal syndrome (rebound insomnia, anxiety, tremor, dizziness, nausea, fits and delirium) may be precipitated

• Acute chronic pain - paradoxical excitement may be induced or important symptoms masked.

• Prolonged use may result in dependence of the alcohol-barbiturate type. Care should be taken in treating patients with a history of drug abuse or alcoholism.

Effects on Phenobarbital	Effects of phenobarbital on other medicines
• Alcohol - concurrent administration with	Phenobarbital increases the rate of metabolism
alcohol may lead to an additive CNS	reducing serum concentrations of the following
depressant effect. This is likely with	drugs:
concurrent administration with other CNS	• Anti-arrhythmics – disopyramide and quinidine
depressants.	loss of arrhythmia control is possible. Plasma levels
	of antiarrhymics should be monitored, if

Page **19** of **78**



Antidoprogranta including MAQIa SSDIa	nhanahamital is added on withdrawn. Changes in
	phenobarbital is added or withdrawn. Changes in
and tricyclics may antagonise the antiepileptic	
	• Antibacterials – chloramphenicol, doxycycline,
convulsive threshold	metronidazole and rifampicin. Avoid concomitant
	use of telithromycin during and for 2 weeks after
concentrations increased by oxcarbazepine,	
phenytoin and sodium valproate. Vigabatrin	-
possibly decreases phenobarbital plasma	• Antidepressants – paroxetine, mianserin and
concentrations.	tricyclic antidepressants.
• Antipsychotics – concurrent use of	• Antiepileptics – carbamazepine, lamotrigine,
chlorpromazine and thioridazine with	tiagabine, zonisamide, primidone and possibly
phenobarbital can reduce the serum levels of	ethosuxamide.
either drug.	• Antifungals – the antifungal effects of
• Folic acid – if folic acid supplements are	griseofulvin can be reduced or even abolished by
given to treat folate deficiency, which can be	concurrent use. Phenobarbital possibly reduces
caused by the use of phenobarbital, the serum	
phenobarbital levels may fall, leading to	-
decreased seizure control in some patients. (see	-
section 4.6).	• Antipsychotics – phenobarbital possibly reduces
• Memantine – the effect of Phenobarbital is	
possibly reduced.	• Antivirals – phenobarbital possibly reduces
1 V	plasma levels of abacavir, amprenavir, darunavir,
	lopinavir, indinavir, nelfinavir, saquinavir.
• St John's wort (Hypericum perforatum) – the	
	• Aprepitant – phenobarbital possibly reduces
concomitant use of the herbal remedy St John's	
wort.	• Beta-blockers – metoprolol, timolol and possibly
	propranolol.
	• Calcium channel blockers – phenobarbital causes
	reduced levels of felodipine, isradipine, diltiazem,
	verapamil, nimodipine and nifedipine and an
	increase in dosage may be required.
	• Cardiac Glycosides – blood levels of digitoxin can
	be halved by concurrent use.
	Ciclosporin or tacrolimus.
	Corticosteroids.
	• Cytotoxics – phenobarbital possibly reduces the
	plasma levels of etoposide or irinotecan.
	• Diuretics – concomitant use with eplerenone
	should be avoided.



• Haloperidol- serum levels are approximately
halved by concurrent used with phenobarbital.
• Hormone Antagonists – gestrinone and possibly
toremifene.
• Methadone – levels can be reduced by concurrent
use of phenobarbital and withdrawal symptoms
have been reported in patients maintained on
methadone when phenobarbital has been added.
Increases in the methadone dosage may be
necessary.
• Montelukast.
• Oestrogens – reduced contraceptive effect.
• Progestogens – reduced contraceptive effect.
• Sodium oxybate - enhanced effects, avoid
concomitant use.
• Theophylline – may require an increase in
theophylline dose.
• Thyroid hormones-may increase requirements for
thyroid hormones in hypothyroidism.
• Tibolone
• Tropisetron
• Vitamins – barbiturates possibly increase
requirements for vitamin D

Phenobarbital may interfere with some laboratory tests including metyrapone test, phenlolamine tests and serum bilirubin estimation.

4.6 Pregnancy and lactation

Phenobarbital therapy in epileptic pregnant women presents a risk to the fetus in terms of major and minor congenital defects such as congenital craniofacial, digital abnormalities and, less commonly, cleft lip and palate. The risk of teratogenic effects developing appears to be greater if more than one antiepileptic drug is administered. The risk to the mother, however is greater if phenobarbital is withheld and seizure control is lost. The risk: benefit balance, in this case, favours continued use of the drug during pregnancy at the lowest possible level to control seizures.

Patients taking phenobarbital should be adequately supplemented with folic acid before conception and during pregnancy. Folic acid supplementation during pregnancy can help to reduce the risk of neural defects to the infant.

Phenobarbital readily crosses the placenta following oral administration and is distributed throughout fetal tissue, the highest concentrations being found in the placenta, fetal liver and brain. Adverse effects on neurobehavioral development have also been reported.

Page **21** of **78**



Haemorrhage at birth and addiction are also a risk. Prophylactic treatment with vitamin K^1 for the mother before delivery (as well as the neonate) is recommended, the neonate should be monitored for signs of bleeding.

Phenobarbital is excreted into breast milk and there is a small risk of neonatal sedation. Breast feeding is therefore not advisable.

4.7 Effects on ability to drive and use machines

Phenobarbital may impair the mental and/or physical abilities required for the performance of potentially hazardous tasks such as driving a car or operating machinery. Patients should be advised to make sure they are not affected before undertaking any potentially hazardous tasks.

4.8 Undesirable effects

• *Blood and the lymphatic system disorders:* megaloblastic anaemia (due to folate deficiency), agranulocytosis, thrombocytopenia.

•Metabolism and nutritional disorders: osteomalacia, rickets.

There have been reports of decreased bone mineral density, osteopenia, osteoporosis and fractures in patients on long-term therapy with phenobarbital. The mechanism by which phenobarbital affects bone metabolism has not been identified.

•*Psychiatric disorders:* paradoxical reaction (unusual excitement), hallucinations, restlessness and confusion in the elderly, mental depression, memory and cognitive impairment, drowsiness, lethargy.

•Nervous system disorders: hyperactivity, behavioural disturbances in children, ataxia, nystagmus.

•Cardiac disorders: hypotension.

•*Respiratory disorders:* respiratory depression.

•Hepato-bilary: hepatitis, cholestasis.

•*Skin and subcutaneous tissue disorders:* allergic skin reactions (maculopapular morbilliform or scarlatiniform rashes), other skin reactions such as exfoliative dermatitis, erythema multiforme.

Severe cutaneous adverse reactions (SCARs): Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) have been reported.

Frequency: very rare

•*General disorders and administration site conditions:* antiepileptic hypersensitivity syndrome (features include fever, rash, lymphadenopathy, lymphocytosis, eosinophilia, haematological abnormalities, hepatic and other organ involvement including renal and pulmonary systems which may become life threatening).

• *Blood and the lymphatic system disorders:* megaloblastic anaemia (due to folate deficiency), agranulocytosis, thrombocytopenia.

•Metabolism and nutritional disorders: osteomalacia, rickets.

Page 22 of 78



There have been reports of decreased bone mineral density, osteopenia, osteoporosis and fractures in patients on long-term therapy with phenobarbital. The mechanism by which phenobarbital affects bone metabolism has not been identified.

•*Psychiatric disorders:* paradoxical reaction (unusual excitement), hallucinations, restlessness and confusion in the elderly, mental depression, memory and cognitive impairment, drowsiness, lethargy.

•Nervous system disorders: hyperactivity, behavioural disturbances in children, ataxia, nystagmus.

•Cardiac disorders: hypotension.

•Respiratory disorders: respiratory depression.

•*Hepato-bilary:* hepatitis, cholestasis.

•*Skin and subcutaneous tissue disorders:* allergic skin reactions (maculopapular morbilliform or scarlatiniform rashes), other skin reactions such as exfoliative dermatitis, erythema multiforme.

Severe cutaneous adverse reactions (SCARs): Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) have been reported.

Frequency: very rare

•*General disorders and administration site conditions:* antiepileptic hypersensitivity syndrome (features include fever, rash, lymphadenopathy, lymphocytosis, eosinophilia, haematological abnormalities, hepatic and other organ involvement including renal and pulmonary systems which may become life threatening).

4.9 Overdose

Toxicity varies between patients; tolerance will develop with chronic use. Features of poisoning are to be expected after ingestion of 1g in adults.

Features:

Drowsiness, dysarthria, ataxia, nystagmus and disinhibition. There may also be coma, cardiovascular collapse, cardiac arrest, hypotension, hypotonia, hypotensia, hypothermia, hypotension and respiratory depression.


Barbiturates decrease gut motility, which may lead to slow onset and worsening of symptoms or cyclical improvement and worsening of symptoms.

Management:

Consider activated charcoal (50g for an adult, 10-15g for a child under 5 years) if more than 10mg/kg body weight of phenobarbital has been ingested within 1 hour, provided the airway can be protected. Repeat dose activated charcoal is the best method of enhancing elimination of phenobarbital in symptomatic patients. In severe hypotension dopamine or dobutamine can be used. Treat rhabdomyolysis with urinary alkalinistion. Haemodialysis or haemofiltration may be required for cases of acute renal or severe hyperkalaemia.

Charcoal haemoperfusion is the treatment of choice for the majority of patients with severe barbiturate poisoning who fail to improve, or who deteriorate despite good supportive care.

Page 23 of 78





5. Pharmacological properties

5.1 Pharmacodynamic properties

ATC CODE: N03A A02

Phenobarbital is a long-acting barbiturate, which because of its depressant effect on the motor cortex, is used in the treatment of epilepsy.

Phenobarbital has a widespread depressant action on cerebral function. It has sedative effects and has some protective action against all varieties of human partial and generalised epilepsy, with the exception of absence seizures. Phenobarbital is also effective in preventing seizures in the corresponding experimental animal models of epilepsy. In different studies phenobarbital appears to have had inconsistent effects in suppressing experimental epileptic foci, and epileptic after-discharges, but it inhibits synaptic transmission, at least in the spinal cord. The drug's probable biochemical mechanism of action is through prolonging the opening time of Cl^- ion channels in postsynaptic neuronal membranes. This effect causes membrane hyperpolarisation and thus impairs nerve impulse propagation. Phenobarbital also decreases intraneuronal Na⁺concentrations, and inhibits Ca^{2+} influx into depolarised synaptosomes. It raises brain serotonin levels, and inhibits noradrenaline (norepinephrine) reuptake into synaptosomes. These additional biochemical actions may contribute towards the anticonvulsant effects of the drug.

5.2 Pharmacokinetic properties

Absorption – Phenobarbital is readily absorbed from the gastrointestinal tract, although it is relatively lipid – insoluble; peak concentrations are reached in about 2 hours after oral administration.

Distribution – Phenobarbital is about 45 to 60% bound to plasma proteins. Phenobarbital crosses the placental barrier and is distributed into breast milk.

Metabolism – the plasma half life is about 75 to 120 hours in adults but is greatly prolonged in neonates, and shorter (about 21 to 75 hours) in children. There is considerable interindividual variation in phenobarbital kinetics. Phenobarbital in only partly metabolised in the liver.

Elimination – about 25% of a dose is excreted in the urine unchanged at normal urinary pH.

ire Laooratori

5.3 Preclinical safety data Not applicable.

6. Pharmaceutical particulars6.1 List of excipientsLactose monohydrateMaize Starch

Microcrystalline cellulose P.V.P.K.-30 Colloidal silicon dioxide

Page **24** of **78**



ire Laboratories.

Purified talc Magnesium stearate Sodium starch glycolate Crosscarmellose sodium Purified water

6.2 Incompatibilities

Incompatible with macrogol.

6.3 Shelf life

36 months

6.4 Special precautions for storage

Store at a temperature not exceeding 30° C. Protect from light & moisture.

6.5 Nature and contents of container

Verbital-100 is supplied in blister of 10 tablets, 10 such blister in 1 carton (10x10)

6.6 Special precautions for disposal and other handling

Not applicable.

7. MARKETING AUTHORISATION HOLDER AND MANUFACTURING SITE ADDRESSES

Marketing Authorisation Holder Abacus Pharma (A) Ltd. BP 4344, B1 -85 K.CT Market Kigali, Rwanda

Manufacturing Site:

Verve Human Care Laboratories 15-A, Pharmacity, Selaqui, Dehradun-248011 India

8. MARKETING AUTHORISATION NUMBER

Not Applicable

9. DATE OF FIRST REGISTRATION/RENEWAL OF THE REGISTRATION Not Applicable

Page **25** of **78**



10. DATE OF REVISION OF THE TEXT Not Applicable

11. DOSIMETRY (IF APPLICABLE)

Not Applicable

12. INSTRUCTIONS FOR PREPARATION OF RADIOPHARMACEUTICALS (IF APPLICABLE)

Not Applicable



Page **26** of **78**